Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

Abstract Background Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer effica...

Full description

Bibliographic Details
Main Authors: Gerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries, Steven de Jong
Format: Article
Language:English
Published: BMC 2017-03-01
Series:BMC Cancer
Subjects:
Metformin
Everolimus
Glycolysis
Hypoxia
Breast cancer
Metabolism
Online Access:http://link.springer.com/article/10.1186/s12885-017-3230-8

Internet

http://link.springer.com/article/10.1186/s12885-017-3230-8

Similar Items